Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Reinhard Dummer(University Hospital of Zurich), Ulrich Keilholz(German Cancer Research Center), Nicole Lindenblatt(University Hospital of Zurich), George Pentheroudakis(Hellenic Cooperative Oncology Group), Axel Hauschild(University Hospital Schleswig-Holstein)
Cited by 393
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k